Differential diagnosis of Parkinson's and multiple system atrophy in non-human primate models using a novel a-synuclein retinal contrast agent and AI-assisted analytics

项目摘要 帕金森病（PD）是仅次于阿尔茨海默病的第二大常见神经退行性疾病， 也是导致65岁以上人群残疾的主要原因。PD属于一系列疾病， “突触核蛋白病”，定义为不溶性突触α-突触核蛋白的进行性聚集，包括 其他疾病如多系统萎缩和路易体痴呆。目前，还没有客观的测试 可以用来明确诊断帕金森病此外，突触核蛋白病的鉴别诊断是非常重要的。 具有挑战性，并严重依赖于医生的临床评估。该领域的一个关键目标是可靠地识别 突触核蛋白病在疾病的早期，无症状阶段，以允许最好的机会，正确的疾病 修改或预防性治疗才有效。该提案旨在开发一种小分子荧光 视网膜造影剂作为PD和其他相关突触核蛋白病的新诊断剂。

Project Summary Parkinson’s Disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease, and a major cause of disability in individuals over 65 years of age. PD belongs to a spectrum of diseases termed the “synucleinopathies”, defined by the progressive aggregation of insoluble fibrillary a-synuclein, and includes other disorders such as multiple system atrophy and Lewy body dementia. Currently, there are no objective tests that can be used to definitively diagnose PD. In addition, differential diagnosis of synucleinopathies is very challenging and relies heavily on a physician's clinical evaluation. A critical goal in the field is to reliably identify synucleinopathies at early, asymptomatic stages of the disease, to allow the best chance for correct disease modifying or preventative treatments to be effective. This proposal aims to develop a small molecule fluorescent retinal contrast agent as a novel diagnostic for PD and other related synucleinopathies.